SECONDARY PROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) WITH LOW DOSE APIXABAN OR RIVAROXABAN: RESULTS FROM A PATIENT POPULATION WITH MORE THAN 2 YEARS OF MEDIAN FOLLOW-UP

Background: Direct oral anticoagulants (DOACs) are widely used for the treatment and secondary prophylaxis of venous thromboembolism (VTE). Nowadays, DOACs represent the gold standard for long-term anticoagulation, with low-intensity DOACs administration becoming increasingly used worldwide in such...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Alessandro Laganà, Giovanni Manfredi Assanto, Chiara Masucci, Mauro Passucci, Livia Donzelli, Alessandra Serrao, Erminia Baldacci, Cristina Santoro, Antonio Chistolini
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	PAGEPress Publications 2024-02-01
סדרה:	Mediterranean Journal of Hematology and Infectious Diseases
נושאים:	dose-reduced Deep vein thrombosis Direct oral anticoagulants (DOACs) Venous thromboembolism secondary prophylaxis VTE recurrence Bleeding adverse events
גישה מקוונת:	https://www.mjhid.org/mjhid/article/view/5567
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!